国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Escherichia coli O9:H4 Elongation factor P (efp) CSB-YP422106EJF
CSB-EP422106EJF
CSB-BP422106EJF
CSB-MP422106EJF
CSB-EP422106EJF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O9:H4 Adenylosuccinate synthetase (purA) CSB-YP422107EJF
CSB-EP422107EJF
CSB-BP422107EJF
CSB-MP422107EJF
CSB-EP422107EJF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O9:H4 Primosomal replication protein n (priB) CSB-YP422108EJF
CSB-EP422108EJF
CSB-BP422108EJF
CSB-MP422108EJF
CSB-EP422108EJF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O9:H4 Fructose-1,6-bisphosphatase class 1 (fbp) CSB-YP422109EJF
CSB-EP422109EJF
CSB-BP422109EJF
CSB-MP422109EJF
CSB-EP422109EJF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O9:H4 Phosphoglycerol transferase I (mdoB), partial CSB-YP422110EJF1
CSB-EP422110EJF1
CSB-BP422110EJF1
CSB-MP422110EJF1
CSB-EP422110EJF1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O9:H4 Purine nucleoside phosphorylase DeoD-type (deoD) CSB-YP422111EJF
CSB-EP422111EJF
CSB-BP422111EJF
CSB-MP422111EJF
CSB-EP422111EJF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Chromatin protein Cren7 (creN7) CSB-YP422112ILH
CSB-EP422112ILH
CSB-BP422112ILH
CSB-MP422112ILH
CSB-EP422112ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis 30S ribosomal protein S4P (rps4p) CSB-YP422113ILH
CSB-EP422113ILH
CSB-BP422113ILH
CSB-MP422113ILH
CSB-EP422113ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Endonuclease V (nfi) CSB-YP422114ILH
CSB-EP422114ILH
CSB-BP422114ILH
CSB-MP422114ILH
CSB-EP422114ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Phosphoribosyl-AMP cyclohydrolase (hisI) CSB-YP422115ILH
CSB-EP422115ILH
CSB-BP422115ILH
CSB-MP422115ILH
CSB-EP422115ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Proteasome subunit beta 1 (psmB1) CSB-YP422116ILH
CSB-EP422116ILH
CSB-BP422116ILH
CSB-MP422116ILH
CSB-EP422116ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Protein CrcB homolog (crcB), partial CSB-YP422117ILH1
CSB-EP422117ILH1
CSB-BP422117ILH1
CSB-MP422117ILH1
CSB-EP422117ILH1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis 50S ribosomal protein L37e (rpl37e) CSB-YP422118ILH
CSB-EP422118ILH
CSB-BP422118ILH
CSB-MP422118ILH
CSB-EP422118ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis UPF0103 protein Igni_0992 (Igni_0992) CSB-YP422119ILH
CSB-EP422119ILH
CSB-BP422119ILH
CSB-MP422119ILH
CSB-EP422119ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Glutamate--tRNA ligase (gltX), partial CSB-YP422120ILH
CSB-EP422120ILH
CSB-BP422120ILH
CSB-MP422120ILH
CSB-EP422120ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis Acidic ribosomal protein P0 homolog (rplP0) CSB-YP422121ILH
CSB-EP422121ILH
CSB-BP422121ILH
CSB-MP422121ILH
CSB-EP422121ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis 50S ribosomal protein L2P (rpl2p) CSB-YP422122ILH
CSB-EP422122ILH
CSB-BP422122ILH
CSB-MP422122ILH
CSB-EP422122ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ignicoccus hospitalis 30S ribosomal protein S8P (rps8p) CSB-YP422123ILH
CSB-EP422123ILH
CSB-BP422123ILH
CSB-MP422123ILH
CSB-EP422123ILH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Citrobacter koseri Ribonuclease P protein component (rnpA) CSB-YP422124CWS
CSB-EP422124CWS
CSB-BP422124CWS
CSB-MP422124CWS
CSB-EP422124CWS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Citrobacter koseri tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG (mnmG), partial CSB-YP422125CWS
CSB-EP422125CWS
CSB-BP422125CWS
CSB-MP422125CWS
CSB-EP422125CWS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>